Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients

• Published in: Journal of antimicrobial chemotherapy Vol. 71; no. 2; pp. 513 - 520
• Main Authors: Join-Lambert, Olivier, Coignard-Biehler, Hélène, Jais, Jean-Philippe, Delage, Maïa, Guet-Revillet, Hélène, Poirée, Sylvain, Duchatelet, Sabine, Jullien, Vincent, Hovnanian, Alain, Lortholary, Olivier, Nassif, Xavier, Nassif, Aude
• Format: Journal Article
• Language: English
• Published: England Oxford Publishing Limited (England) 01.02.2016
• Subjects: Adolescent; Adult; Anti-Bacterial Agents - therapeutic use; Antibiotics; beta-Lactams - therapeutic use; Combined Modality Therapy - methods; Female; Hidradenitis Suppurativa - drug therapy; Hidradenitis Suppurativa - pathology; Hidradenitis Suppurativa - surgery; Humans; Male; Medical treatment; Middle Aged; Pilot Projects; Retrospective Studies; Severity of Illness Index; Skin diseases; Surgical Procedures, Operative - methods; Treatment Outcome; Young Adult
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkv361

Hidradenitis suppurativa (HS) is an inflammatory skin disease typically localized in the axillae and inguinal and perineal areas. In the absence of standardized medical treatment, severe HS patients present chronic suppurative lesions with polymicrobial anaerobic abscesses. Wide surgery is the cornerstone treatment of severe HS, but surgical indications are limited by the extent of lesions. Intravenous broad-spectrum antibiotics may help control HS, but their efficacy is not documented. This study was designed to assess the efficacy of a 6 week course of ertapenem (1 g daily) and of antibiotic consolidation treatments for 6 months (M6) in severe HS. Thirty consecutive patients with severe HS were retrospectively included in this study. The clinical severity of HS was assessed using the Sartorius score, which takes into account the number and severity of lesions. The median (IQR) Sartorius score dropped from 49.5 (28-62) at baseline to 19.0 (12-28) after ertapenem (P < 10(-4)). Five patients were lost to follow-up thereafter. At M6 the Sartorius score further decreased for the 16 patients who received continuous consolidation treatments, since 59% of HS areas reached clinical remission at M6 (i.e. absence of any inflammatory symptoms, P < 10(-4)). Nine patients interrupted or received intermittent consolidation treatments due to poor observance or irregular follow-up. Their Sartorius score stopped improving or returned to baseline. No major adverse event occurred. Ertapenem can dramatically improve severe HS. Consolidation treatments are needed to further improve HS and are mandatory to prevent relapses. Combined with surgery, optimized antibiotic treatments may be promising in severe HS.